tetano
Editor, Senior Moderator
J Clin Med
. 2021 Nov 24;10(23):5498.
doi: 10.3390/jcm10235498.
Immunogenicity of BNT162b2 mRNA COVID-19 Vaccine in Patients with Cardiovascular Disease
Hiroyuki Naruse[SUP] 1 [/SUP], Hiroyasu Ito[SUP] 2 [/SUP], Hideo Izawa[SUP] 3 [/SUP], Masayoshi Sarai[SUP] 3 [/SUP], Junnichi Ishii[SUP] 4 [/SUP], Eirin Sakaguchi[SUP] 1 [/SUP], Reiko Murakami[SUP] 2 [/SUP], Tatsuya Ando[SUP] 2 [/SUP], Hidetsugu Fujigaki[SUP] 5 [/SUP], Kuniaki Saito[SUP] 5 [/SUP]
Affiliations
Abstract
Concern has been raised about the effectiveness of the coronavirus disease 2019 (COVID-19) vaccine in the population of patients with various comorbidities such as heart disease. We investigated the humoral response to the BNT162b2 mRNA COVID-19 vaccine in patients with cardiovascular disease (CVD). We measured IgG against severe acute respiratory syndrome coronavirus 2 spike receptor-binding domain (RBD-IgG) in 85 CVD patients and 179 healthcare workers (HCWs). Blood samples were collected from patients and HCWs three times: (1) before the first dose of vaccination, (2) two weeks after the first dose of vaccination, and (3) two weeks after the second dose of vaccination. Patients with CVD showed a significantly inferior serological response to the BNT162b2 mRNA COVID-19 vaccine at 14 days after the prime dose compared to HCWs (21% vs. 95%, p < 0.001). Median RBD-IgG titers of patients with CVD at 14 days after the second dose were significantly lower than those of HCWs (137.2 U/mL (80.6-200.4 U/mL) vs. 176.2 U/mL (123.9-260.0 U/mL), p < 0.001). In multivariable analyses, CVD is significantly associated with seropositivity after first vaccination and RBD-IgG titers after second vaccination. CVD patients may have a poor humoral response to the BNT162b2 mRNA COVID-19 vaccine, need to be closely monitored, and require earlier revaccination to ensure stronger immunity and protection against infection.
Keywords: cardiovascular disease; coronavirus disease 2019 (COVID-19); immunogenicity; vaccine.
. 2021 Nov 24;10(23):5498.
doi: 10.3390/jcm10235498.
Immunogenicity of BNT162b2 mRNA COVID-19 Vaccine in Patients with Cardiovascular Disease
Hiroyuki Naruse[SUP] 1 [/SUP], Hiroyasu Ito[SUP] 2 [/SUP], Hideo Izawa[SUP] 3 [/SUP], Masayoshi Sarai[SUP] 3 [/SUP], Junnichi Ishii[SUP] 4 [/SUP], Eirin Sakaguchi[SUP] 1 [/SUP], Reiko Murakami[SUP] 2 [/SUP], Tatsuya Ando[SUP] 2 [/SUP], Hidetsugu Fujigaki[SUP] 5 [/SUP], Kuniaki Saito[SUP] 5 [/SUP]
Affiliations
- PMID: 34884205
- DOI: 10.3390/jcm10235498
Abstract
Concern has been raised about the effectiveness of the coronavirus disease 2019 (COVID-19) vaccine in the population of patients with various comorbidities such as heart disease. We investigated the humoral response to the BNT162b2 mRNA COVID-19 vaccine in patients with cardiovascular disease (CVD). We measured IgG against severe acute respiratory syndrome coronavirus 2 spike receptor-binding domain (RBD-IgG) in 85 CVD patients and 179 healthcare workers (HCWs). Blood samples were collected from patients and HCWs three times: (1) before the first dose of vaccination, (2) two weeks after the first dose of vaccination, and (3) two weeks after the second dose of vaccination. Patients with CVD showed a significantly inferior serological response to the BNT162b2 mRNA COVID-19 vaccine at 14 days after the prime dose compared to HCWs (21% vs. 95%, p < 0.001). Median RBD-IgG titers of patients with CVD at 14 days after the second dose were significantly lower than those of HCWs (137.2 U/mL (80.6-200.4 U/mL) vs. 176.2 U/mL (123.9-260.0 U/mL), p < 0.001). In multivariable analyses, CVD is significantly associated with seropositivity after first vaccination and RBD-IgG titers after second vaccination. CVD patients may have a poor humoral response to the BNT162b2 mRNA COVID-19 vaccine, need to be closely monitored, and require earlier revaccination to ensure stronger immunity and protection against infection.
Keywords: cardiovascular disease; coronavirus disease 2019 (COVID-19); immunogenicity; vaccine.